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ORIGINAL ARTICLE
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ABSTRACT
Objective: To evaluate the incidence of gestational diabetes mellitus (GDM) using the one-step
as compared with the two-step approach.
Study design: This was a parallel group nonblinded randomized trial conducted at Thomas
Jefferson University Hospital (TJUH) in Philadelphia, Pennsylvania from June 2016 to December
2016. The primary outcome was GDM incidence in the one-step compared to the two-approach.
Pregnant women without a history of pregestational diabetes were offered screening for GDM
at gestational age 24–28 weeks. Obese women, defined as having a BMI 30 kg/m2, as well as
those with a history of a pregnancy complicated by GDM, a history of a macrosomic baby
(>4000 g), or with polycystic ovarian syndrome (PCOS), were offered early screening at their ini-
tial prenatal visit, and screening was repeated at 24–28 weeks if initially normal. Women were
excluded if they had pre-existing diabetes or had a history of bariatric surgery. Women who
were eligible were randomized in a 1:1 ratio to either the one-step or two-step approaches. A
sample size of 142 women was planned per group. Women randomized to the one-step
approach, after an overnight fast, were given a 2-h glucose tolerance test, which consisted of a
75-g glucose load. Blood glucose levels were measured fasting, at 1 h and 2h after the glucose
load. Diagnostic cutoffs for GDM diagnosis were one value of either fasting 92mg/dL, 1 h
180mg/dL, or 2 h 153mg/dL, respectively. Women randomized to the two-step approach
were given a nonfasting 50-g glucose load, and the blood glucose level was measured an hour
after the glucose load. If that value was 135mg/dL, the patient had a 3-h glucose tolerance
test consisting of a 100-g glucose load. Diagnostic cutoffs for GDM diagnosis for this 3-h test
were 2 abnormal values of fasting 95mg/dL, 1 h 180mg/dL, 2 h 155mg/dL and 3h
140mg/dL, respectively. All analyses were done using an intention-to-treat approach, evaluat-
ing women according to the treatment group to which they were randomly allocated.
Results: Two hundred eighty-four women agreed to take part in the study and underwent ran-
domization from June 2015 to December 2015. Of them, 249 completed the screening and
were followed up for the primary endpoint. Out of the 249 women who completed the screen-
ing, 123 were assigned to the one-step group and 126 to the two-step group. GDM occurred in
10 women (8.1%) in the one-step group, and 7 women (5.6%) in the two-step group (p¼ .42).
Preeclampsia, preterm birth (PTB), induction of labor, mode of delivery and incidence of gesta-
tional age (OASIS) were not significantly different. Perinatal outcomes were similar as well.
Conclusions: Screening for GDM with one-step, compared with the two-step approach, resulted
in a similar incidence of GDM.
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Gestational diabetes mellitus (GDM) is associated with
significant maternal and neonatal morbidity [1–5].
Screening for GDM has been the subject of much
debate. The American College of Obstetricians &
Gynecologists (ACOG) currently recommends screening
with the two-step approach, starting with an initial
50-g glucose challenge test (GCT) followed, if the GCT
is abnormal, by a 100 g oral glucose tolerance test
(OGTT) [6].
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In 2008, the Hyperglycemia and Pregnancy
Outcome (HAPO) study demonstrated a linear relation-
ship between maternal glycemic control and adverse
pregnancy outcomes, screening with a one-step
approach using a 75 g OGTT [7]. In 2010, in an effort
to promote a more unified global guideline for screen-
ing and diagnosing GDM, the International Association
of Diabetes in Pregnancy Study Group (IADPSG)
adopted GDM screening based on the results of the
HAPO study [8].
However, this decision has not been without con-
troversy. Specifically, the one-step approach using a
75 g OGTT leads to a considerably lower threshold for
GDM diagnosis than the two-step approach. The one-
step approach has resulted in an increased GDM inci-
dence, up to 18% [8], as compared to approximately
6% using the two-step approach [6]. The incidence,
however, varies widely in different populations and
carries possible clinical implications on obstetrical
practice [9–15]. As a result, national and international
organizations have set differing guidelines for screen-
ing and diagnosing GDM, some recommending the
two-step approach (e.g. ACOG) [6] while others the
one-step approach (e.g. IADPSG, WHO, FIGO, American
Endocrine Society) [7,8,16–18]. Moreover, the random-
ized controlled trials comparing the incidence of GDM
using the one-step versus the two-step approach have
shown differing results [11,12,19].
The aim of our study was to evaluate the incidence
of GDM using the one-step as compared with the
two-step approach in randomized controlled
trial (RCT).
Materials and methods
This was a parallel group nonblinded RCT conducted
at Thomas Jefferson University Hospital (TJUH) in
Philadelphia, Pennsylvania. Institutional Review Board
(IRB) approval was obtained before active patient
recruitment.
All pregnant women without a history of pregesta-
tional diabetes were offered screening for GDM at ges-
tational age 24–28 weeks. Obese women, defined as
having a BMI 30 kg/m2, as well as those with a his-
tory of a pregnancy complicated by GDM, a history of
a macrosomic baby (>4000 g), or with polycystic ovar-
ian syndrome (PCOS), were offered early screening at
their initial prenatal visit, and screening was repeated
at 24–28 weeks if initially normal. Women were
excluded if they had pre-existing diabetes or had a
history of bariatric surgery. Women meeting these cri-
teria were consented and then randomized to GDM
screening with either the one-step or two-step
approaches.
Randomization was based on a 1:1 computer-gener-
ated schema in random-sized blocks (size 4, 6 and 8).
Sequentially numbered opaque envelopes were used
to mask the allocation until patient’s consent was
given to participate in the study, at which time ran-
domization and allocation was performed. Patients
and clinicians were unblinded to the screening test
they were assigned to.
For the women randomized to the one-step
approach, after an overnight fast, they were given a
2-hour glucose tolerance test, which consisted of a
75-g glucose load as recommended by IADPSG [8].
Blood glucose levels were measured fasting, at 1 and
2 h after the glucose load. Diagnostic cutoffs for GDM
diagnosis were one value of either fasting 92mg/dL,
1 h  180mg/dL, or 2 h  153mg/dL, respectively.
For women randomized to the two-step approach,
they were given a nonfasting 50-g glucose load as rec-
ommended by ACOG [6], and the blood glucose level
was measured an hour after the glucose load. If that
value was 135mg/dL, the patient had a 3-h glucose
tolerance test consisting of a 100-g glucose load.
Diagnostic cutoffs for GDM diagnosis for this 3-h test
were 2 abnormal values of fasting 95mg/dL, 1 h
180mg/dL, 2 h 155mg/dL and 3h 140mg/dL,
respectively.
Gestational age was confirmed on all women
prior to their 24–28 weeks GDM screening. Once
GDM diagnosis was made, all women met with a
dietician and a diabetic educator. Subsequently,
blood-glucose selfmonitoring was initiated four times
per day (fasting, and 2-h postprandial) using a port-
able glucometer. Medical treatment was started ini-
tially with an oral hypoglycemic agent usually if
>30% of blood glucose values were elevated (fasting
glucose level >95mg/dL and 2-h postprandial
>120mg/dL). If treatment with an oral agent, either
metformin or glyburide, was maximized and blood
glucose control remained suboptimal (>30% of blood
glucose values still elevated, i.e. fasting glucose level
>95mg/dL 2-h postprandial >120mg/dL), insulin
treatment was recommended.
Diet-controlled GDM patients did not have any
extra antenatal surveillance. For women requiring
medical treatment for GDM, nonstress testing was per-
formed weekly starting at 32 weeks and then twice
weekly starting at 36 weeks, along with serial growth
scans every 4 weeks. Delivery at 39 0/7 to 39 6/7
week was recommended to all women with GDM on
medical treatment.
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All analyses were done using an intention-to-treat
approach, evaluating women according to the treat-
ment group to which they were randomly allocated.
The primary outcome was the incidence of GDM.
Maternal secondary outcomes included preeclampsia,
preterm birth (PTB)< 37 weeks, induction of labor,
mode of delivery and obstetric anal sphincter injuries
(OASIS). Perinatal secondary outcomes included birth
weight, large for gestational age (LGA) (defined as
estimated fetal weight on antenatal ultrasound >90th
percentile), intrauterine growth restriction (IUGR)
(defined as estimated fetal weight on antenatal ultra-
sound <10th percentile), polyhydramnios (defined as
maximum vertical pocket >8 cm, or amniotic fluid
index >24 cm), macrosomia (defined as birth weight
>4000 g), shoulder dystocia, 5min Apgar score <7,
neonatal hypoglycemia (defined as glucose <40mg/
dL), neonatal hyperbilirubinemia requiring photother-
apy, stillbirth (defined as intrauterine fetal demise >20
weeks), neonatal death (defined as death of a live-
born infant within the first 28 days of live) and peri-
natal death (defined as either stillbirth or neonatal
death).
Our sample size calculation was based on a GDM
incidence increase from 6% as an average background
rate of GDM in the USA to an 18% GDM rate as antici-
pated according to the HAPO trial [9]. We calculated
that with a sample size of 284 (142 in each group),
the study would have at least 80% power with an
alpha of 0.05.
Data analyses for this study were generated using
Statistical Package for Social Sciences (SPSS) v 19.0
(IBM Inc, Armonk, NY). Data are shown as mean± SD,
or as number (percentage). Univariate comparisons
of dichotomous data were performed with the use
of the chi-square test with continuity correction.
Comparisons between groups were performed with
the use of the T-test to test group means by assuming
equal within-group variances. No adjustment for mul-
tiple comparisons was made, so the findings of the
secondary outcomes should be considered explora-
tory. A 2-sided p value less than 0.05 was considered
significant. This trial was registered at ClinicalTrials.gov
(identifier NCT03073330).
Results
Two hundred eighty-four women consented to take
part in the study and underwent randomization. Of
them, 249 completed the screening and were followed
up for the primary endpoint, while 35 never per-
formed any GDM screening. Out of the 249 women
who completed the GDM screening, 123 were
assigned to the one-step group and 126 to the two-
step group (Figure 1).
Overall, 26.9% (67/249) of the women were obese
and 11.6% (29/249) were smokers. The mean age was
about 29 years. Four women (3.3%) in the one-step,
and 3 women (2.4%) in the two-step group had his-
tory of GDM in a prior pregnancy (Table 1).
Figure 1. Study flow chart [25].
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All women who started the screening test in the
one step approach group completed the diagnostic
testing, while 5 (4.2%) in the two-step approach group
did not complete it (p¼ .04). The latter was due to
not presenting for the 3 h OGTT test after an abnormal
result of the nonfasting 1-h 50-g glucose load-
ing dose.
GDM occurred in 10 women (8.1%) in the one-step
group, and 7 women (5.6%) in the two-step group
(p¼ .42) (Table 2).
Data for secondary outcomes were available for 110
women in the one-step group, and for 116 women in
the two-step group (Figure 1). Preeclampsia, PTB,
induction of labor, mode of delivery, and incidence of
OASIS were not significantly different between the
groups (Table 2). Perinatal outcomes were similar as
well (Table 3).
One stillbirth occurred in each group, both in
women diagnosed with GDM by early screening. In
the one-step group, it was associated with a Dandy
Walker malformation. In the two-step group, it was
associated with a spontaneous preterm loss at 22
weeks. No cases of neonatal death were reported in
either group.
Discussion
This nonblinded randomized trial showed that screen-
ing for GDM with the one-step approach, compared
with the two-step approach, resulted in a similar inci-
dence of GDM. The one-step approach was also
associated with a similar incidence of maternal
and perinatal outcomes compared to the two-step
approach.
The 8.1% incidence of GDM using the one-step
IADPSG screening approach was far less than the
anticipated 18% [20]. Studies have reported varying
GDM incidences using the one-step approach, ranging
from 3.6% to 35.5% [9,15–19]. This discrepancy is likely
due to different populations with different predispos-
ing factors for GDM.
The findings from a recent meta-analysis of the
three RCTs published so far in the literature comparing
the one-step to the two-step approach which included
2333 women, showed that the one-step approach for
GDM screening was associated with similar incidences
of GDM (8.4% versus 4.3%), but with significantly
lower incidences of PTB (3.7% versus 7.6%), cesarean
delivery (16.3% versus 22.0%), macrosomia (2.9% ver-
sus 6.9%), neonatal hypoglycemia (1.7 versus 4.5%),
and admission to the intensive care unit (4.4% versus
9.0%) compared to two-step screening [21]. The
results of our RCT reveal very similar nonsignificant




(n¼ 126) p value
GDM 10 (8.1%) 7 (5.6%) .42
Women with GDM receiving
medical treatmenta






Preeclampsia 10 (9.1%) 9 (7.8%) .78
Preterm birth 12 (10.9%) 10 (8.6%) .56
Induction of labor 51 (46.4%) 52 (44.8%) .69
Vaginal Delivery 70 (63.6%) 75 (64.7%) .87
Cesarean delivery 35 (31.8%) 36 (31.0%) .89
Cesarean delivery for arrested labor 3 (2.7%) 10 (8.6%) .57
Operative vaginal delivery 5 (4.6%) 5 (4.3%) .93
OASIS 3 (2.7%) 5 (4.3%) .51
Data are presented as mean ± standard deviation or as number
(percentage).
GDM: gestational diabetes mellitus; GA: gestational age; OASIS: obstetrical
anal sphincter injuries.
aMedical treatment included metformin, glyburide and insulin.
Table 1. Characteristics of the included women.
One-step (n¼ 123) Two-step (n¼ 126)
Age (years) 29.5 ± 5.9 29.5 ± 5.3
Ethnicity
White 40 (32.5%) 47 (37.3%)
Black 64 (52.0%) 61 (48.4%)
Hispanic 6 (4.9%) 3 (2.4%)
Asian 11 (9.0%) 10 (7.9%)
Other/declined to answer 2 (1.6%) 5 (4.0%)
BMI 30 33 (26.8%) 34 (27.0%)
Smoking 8 (6.5%) 21 (16.7%)
Prior GDM 4 (3.3%) 3 (2.4%)
Prior macrosomia 12 (9.8%) 4 (3.2%)
Family history of GDM 42 (34.2%) 39 (31.0%)
Prior cesarean delivery 19 (15.5%) 20 (15.9%)
Chronic hypertension 11 (8.9%) 12 (9.5%)
PCOS 1 (0.8%) 2 (1.6%)
Data are presented as mean ± standard deviation or as number
(percentage).
GDM: gestational diabetes mellitus; PCOS: polycystic ovarian syndrome;
BMI, body mass index; GDM, gestational diabetes mellitus; PCOS, polycys-
tic ovarian syndrome.
p values not significant for all variables.




(n¼ 116) p value
Birth weight (g) 3214 ± 679 3256 ± 482 .82
LGA 3 (2.7%) 5 (4.3%) .51
IUGR 7 (6.4%) 8 (6.9%) .87
Polyhydramnios 6 (5.5%) 4 (3.5%) .46
Macrosomia 9 (8.2%) 7 (6.0%) .53
Shoulder dystocia 0 1 (0.86%) .99
5-min Apgar score< 7 1 (0.9%) 2 (1.7%) .59
Neonatal hypoglycemia 8 (7.3%) 12 (10.4%) .42
Neonatal hyperbilirubinemia
requiring phototherapy
8 (7.3%) 2 (1.7%) .05
Fetal demise >20 weeks 1 (0.9%) 1 (0.9%) .97
Data are presented as mean ± standard deviation or as number
(percentage).
LGA: large for gestational age; IUGR: intrauterine growth restriction.
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incidences of GDM with the one-step versus the two-
step approaches. We found no significant differences
in maternal or perinatal outcomes.
Our study has several strengths. This is the largest
RCT in the USA assessing GDM incidence with the two
most widely used screening approaches. Our study
population is a diverse urban population in the USA
representing a multiethnic cohort along with comor-
bid predisposing factors to GDM.
Our study has several limitations as well. Our pri-
mary outcome was GDM incidence and not a maternal
or perinatal outcome, which are the ultimate goals for
choosing a certain screening test. It was underpow-
ered as there was around a 10% loss rate for the pri-
mary outcome due to some women never having
GDM screening, and the numbers for the secondary
outcomes were about another 10% less due to loss to
follow up. Understandably, our population characteris-
tics may not be reflective of populations in other geo-
graphical locations in the USA or other countries that
may have other GDM predisposing factors.
Since the HAPO study results were published [7]
and endorsed by IADPSG [8] and subsequently WHO
[16] and FIGO [17], there were several concerns in the
USA for adopting the one-step 2-h approach. The NIH
consensus in 2013 rejected the one-step approach as
the preferred GDM screening test due to concern over
additional burden on the American health care system
in view of the 18% anticipated GDM incidence [22].
The performance of a one-step approach, although
fasting, gives the advantage of performing the test
only once. In our study, about 4% of women who had
the two-step approach and an abnormal result on the
1-h GCT, never performed the diagnostic 3-hour GTT
test. More importantly, the one-step approach may
improve the identification of women who had an
abnormal 1-h GCT but a normal 3-h GTT. These
women in particular are at risk of adverse maternal
and perinatal outcomes, such as, for example, gesta-
tional hypertension, preeclampsia, preterm birth, mac-
rosomia and cesarean delivery [23]. This may be
explained by the fact that the two-step approach was
designed to identify women at increased risk for
developing type 2 diabetes [7], while the one-step
approach was designed to identify adverse pregnancy
outcomes based on the HAPO study findings [8].
Given the findings of our RCT, the concern about a
major increase in the incidence of GDM by applying
the IADPSG screening and criteria cutoffs for diagnosis
may not be justified. As such, the cost implications
may not be as high as projected [22]. Also, the identi-
fication of women with GDM and therefore at risk of
developing type 2 diabetes later in life is another
example of using pregnancy as window for future
health [24].
In summary, screening for GDM with one-step,
compared with the two-step approach, resulted in a
similar incidence of GDM. A large, multicenter RCT in
the USA representing different geographic locations
with pregnancy outcomes as a primary outcome, and
a cost-effectiveness analysis, is needed. This may
answer the question if the one-step IADPSG GDM
screening approach is beneficial for mothers and their
babies, and cost-effective.
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